BioNTech SE

BioNTech SE is a biopharmaceutical company described in Chinese VC materials as a "一流企业" (top-tier enterprise) in the sector . Its most prominent appearance in elsewhere's corpus is through a major collaboration with Triastek (三迭纪), a 3D drug-printing company: in July 2024, the two parties reached a research collaboration and platform technology licensing agreement valued at over $1.2 billion in total, to jointly develop oral RNA drugs based on 3D-printed pharmaceutical technology . The deal was flagged by Yunqi Capital as "the first-ever technology platform international collaboration in Chinese pharmaceutical history" . BioNTech also appears in earlier coverage from November 2020, when it and Pfizer jointly announced that their COVID-19 vaccine demonstrated over 90% efficacy .

elsewhere's corpus does not contain detailed background on BioNTech's founding, headquarters, or full business scope beyond these deal references.